EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The effect of common medications on the efficacy of immune checkpoint inhibitors

Daria Brinzevich, Virginia Falvello, Sadiq S Rehmani, Garth W Strohbehn, Nithya Ramnath, Michael P Dykstra iD, Luke M Higgins iD, David Elliott, Matthew J Schipper, Michael D Green iD, Alex K Bryant iD

Cancer · 15.12.2025 · 131 (24)

DOI: 10.1002/cncr.70222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 14.12.2025. Verfasst von Daria Brinzevich und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medications such as proton pump inhibitors (PPIs), antihistamines, and nonsteroidal anti‐inflammatory drugs have been linked to immune checkpoint inhibitor (ICI) efficacy in patients with non–small cell lung cancer (NSCLC), but these associations may reflect unmeasured confounding rather than true pharmacologic effects. This study evaluated whether commonly prescribed medications influence ICI outcomes, using a national patient sample and a negative control cohort.

Methods

The authors identified Veterans Health Administration (VHA) patients with stage IV NSCLC treated with first‐ or second‐line ICI therapy ( n = 3739) or chemotherapy ( n = 6585) from 2005 to 2023. Baseline use of 20 common medication classes and an immunomodulatory drug score were assessed. Propensity‐weighted Cox regression evaluated associations between each medication class and overall survival (OS) or time‐to‐next treatment (TTNT) in the ICI group. For any medication with a nominally significant association ( p < .05), the same analysis was repeated in the chemotherapy group to test for nonspecific effects.

Results

After propensity weighting, 14 of 20 medication classes showed no association with OS or TTNT in the ICI cohort. Loop diuretics, anticoagulants, opioids, penicillin antibiotics, and fluoroquinolone antibiotics were associated with worse outcomes, but similar effects were seen in the chemotherapy group. A higher immunomodulatory drug score was also associated with inferior outcomes among ICI patients, but this association was likewise present in the chemotherapy cohort.

Conclusion

In this study, commonly prescribed medications did not appear to alter ICI efficacy in stage IV NSCLC. Prior associations reported in the literature may be attributable to unmeasured confounding rather than true drug–immunotherapy interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleFemaleAgedMiddle AgedProton Pump InhibitorsUnited StatesAnti-Inflammatory Agents, Non-SteroidalTreatment OutcomeHistamine Antagonists

Stichwörter der Autor:innen

Veterans Healthcarcinomaimmune checkpoint inhibitorsimmunotherapylung neoplasmsnon‐small‐cell lung

Substanzen

Immune Checkpoint InhibitorsProton Pump InhibitorsAnti-Inflammatory Agents, Non-SteroidalHistamine Antagonists

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA.
  • Division of Oncology, LTC Charles S. Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA.
  • Lung Precision Oncology Program, Charles S. Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Rogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.

ORCID-Profile: Michael P Dykstra, Luke M Higgins, Michael D Green, Alex K Bryant

Zitieren

APA

Brinzevich, D., Falvello, V., Rehmani, S. S., Strohbehn, G. W., Ramnath, N., Dykstra, M. P., Higgins, L. M., Elliott, D., Schipper, M. J., Green, M. D., & Bryant, A. K. (2025). The effect of common medications on the efficacy of immune checkpoint inhibitors. Cancer, 131(24). https://doi.org/10.1002/cncr.70222

Vancouver

Brinzevich D, Falvello V, Rehmani SS, Strohbehn GW, Ramnath N, Dykstra MP, et al. The effect of common medications on the efficacy of immune checkpoint inhibitors. Cancer. 2025;131(24). doi:10.1002/cncr.70222

BibTeX
@article{Brinzevich2025,
  author = {Brinzevich, Daria and Falvello, Virginia and Rehmani, Sadiq S and Strohbehn, Garth W and Ramnath, Nithya and Dykstra, Michael P and Higgins, Luke M and Elliott, David and Schipper, Matthew J and Green, Michael D and Bryant, Alex K},
  title = {The effect of common medications on the efficacy of immune checkpoint inhibitors},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {24},
  doi = {10.1002/cncr.70222}
}
Kostenlos starten →